NASDAQ:AKTS

Aktis Oncology (AKTS) Stock Price, News & Analysis

Aktis Oncology logo
$16.31 +0.15 (+0.93%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$16.32 +0.01 (+0.03%)
As of 11/17/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Aktis Oncology Stock (NASDAQ:AKTS)

Advanced

Key Stats

Today's Range
$15.60
▼
$16.47
50-Day Range
$14.59
▼
$24.06
52-Week Range
$13.96
▼
$34.19
Volume
473,264 shs
Average Volume
352,308 shs
Market Capitalization
$879.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.63
Consensus Rating
Moderate Buy

Company Overview

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells.

The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

Aktis Oncology is based in Cambridge, Massachusetts, and focuses on research and clinical development of its radiopharmaceutical platform and product candidates.

AI Generated. May Contain Errors.

Aktis Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

AKTS MarketRank™: 
1.56229180546 of 5 stars

Aktis Oncology scored higher than 31% of companies evaluated by MarketBeat, and ranked 743rd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aktis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Aktis Oncology has a consensus price target of $35.63, representing about 118.4% upside from its current price of $16.31.

  • Amount of Analyst Coverage

    Aktis Oncology has only been the subject of 4 research reports in the past 90 days.

  • Read more about Aktis Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Aktis Oncology are expected to decrease in the coming year, from ($1.94) to ($2.51) per share.

  • Price to Book Value per Share Ratio

    Aktis Oncology has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.23% of the float of Aktis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Aktis Oncology has a short interest ratio ("days to cover") of 16.02, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Aktis Oncology has recently increased by 2.60%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Aktis Oncology does not currently pay a dividend.

  • Dividend Growth

    Aktis Oncology does not have a long track record of dividend growth.

  • News Sentiment

    Aktis Oncology has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Aktis Oncology this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Aktis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive AKTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aktis Oncology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKTS Stock News Headlines

Aktis: Q3 earnings snapshot
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Aktis Oncology reports Q3 results
Aktis Oncology (AKTS) Expected to Release Earnings on Thursday
Aktis Oncology: Padcev Is Building The Market It Wants
See More Headlines

AKTS Stock Analysis - Frequently Asked Questions

Aktis Oncology's stock was trading at $21.75 on January 1st, 2026. Since then, AKTS shares have decreased by 25.0% and is now trading at $16.31.

Aktis Oncology (NASDAQ:AKTS) announced its quarterly earnings data on Thursday, November, 12th. The technology company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.07. The technology company earned $3.91 million during the quarter, compared to the consensus estimate of $4.87 million. Aktis Oncology had a negative net margin of 706.81% and a negative trailing twelve-month return on equity of 26.86%.

Aktis Oncology (AKTS) raised $300 million in an initial public offering on Friday, January 9th 2026. The company issued 17,650,000 shares at a price of $16.00-$18.00 per share.

Aktis Oncology's top institutional shareholders include Blue Owl Capital Holdings LP (6.22%), State Street Corp (1.95%), Mirador Capital Partners LP (0.25%) and Jump Financial LLC (0.21%). Insiders that own company stock include Bioventures 2018 LP Mpm, Vida Ventures Ii, Llc, Helen Susan Kim, Ecor1 Capital, Llc and Ken Herrmann.
View institutional ownership trends
.

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aktis Oncology investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Inseego (INSG), Nokia (NOK), Micron Technology (MU) and Block (XYZ).

Company Calendar

Last Earnings
11/12/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AKTS
CIK
2035832
Fax
N/A
Employees
79
Year Founded
2020

Price Target and Rating

High Price Target
$40.00
Low Price Target
$31.00
Potential Upside/Downside
+118.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.73 million
Net Margins
-706.81%
Pretax Margin
-706.81%
Return on Equity
-26.86%
Return on Assets
-18.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.22
Quick Ratio
14.22

Sales & Book Value

Annual Sales
$6.50 million
Price / Sales
135.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.51 per share
Price / Book
1.92

Miscellaneous

Outstanding Shares
53,920,000
Free Float
N/A
Market Cap
$879.44 million
Optionable
Optionable
Beta
N/A

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:AKTS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners